Amgen Makes All Repatha ® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850 Majority of Repatha Medicare Patients Now Have Access at a Significantly Lower Out-of-Pocket Cost THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor with prefilled cartridge), are now available at a 60 percent reduced list price of $5,850 per y...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news